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justified, we need to implement induction chemotherapy 
to improve the survival of patients with N2 disease. 
We agree with Dr. Van Schil's opinion: "Primary con- 
sideration should be given to induction chemotherapy in 
patients with N2 involvement, avoiding primary surgical 
treatment." The problem is how to detect N2 disease in 
patients with clinical stage I lung cancer before thoracot- 
omies. We have recently performed video-assisted thora- 
coscopic sampling of mediastinal lymph nodes just before 
thoracotomy in patients with clinical stage I lung cancer. 
We detected N2 disease in some patients and treated 
them with induction chemotherapy. We are preparing to 
publish our methods and results of this study. 
Tsuneyo Takizawa, MD 
Masanori Terashima, MD 
Department of Thoracic Surgery 
Niigata Cancer Center Hospital 
Niigata, Japan 
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Concentration of glutaraldehyde in fixation of 
bioprosthetic valves 
To the Editor: 
We read with great interest the article by Duncan, 
Boughner, and Vesely, 1 in which they concluded that 
better stabilization of the porcine aortic valve can be 
achieved if the tissue is fixed dynamically in glutaralde- 
hyde solution. Dynamic fixation stabilizes the tissue within 
3 hours 15 minutes and 24 hours when the porcine aortic 
valves are cross-linked in 0.5% and 0.05% glutaraldehyde, 
respectively, at room temperature. 1 Schoen, Tsao, and 
Levy 2 have noted that complete glutaraldehyde uptake by 
bioprosthetic tissue occurs within 24 hours of incubation. 
However, it was observed that complete glutaraldehyde 
uptake by bioprosthetic tissue did not occur even in 1 
month after the onset of treatment when the tissue was 
preserved in glutaraldehyde solution of a particular con- 
centration) When a tissue is exposed to glutaraldehyde 
solution of a particular concentration for a certain period, 
it becomes resistant to further penetration of glutaralde- 
hyde molecules from the solution of a particular concen- 
tration. At this stage a slight increase in the concentration 
of glutaraldehyde in the preservative solution is enough 
for further access of glutaraldehyde molecules to the 
interstitium of the tissue, which may be documented by 
measuring the concentration of glutaraldehyde of the 
preservative solution before and after treatment. How- 
ever, a sharp increase in concentration of glutaraldehyde 
in the preservative solution may falsely indicate the corn- 
pletion of saturation of the tissue with glutaraldehyde 
after two or three changes owing to rapid interaction with 
the outer surface of the tissue, and this event may impair 
the further penetration of glutaraldehyde molecules) We 
found that complete stabilization can be attained by 
preserving the tissue in glutaraldehyde solution with grad- 
ual increases in concentrations from 0.1% to 0.25% at 4 ° 
to 10 ° C for more than 8 weeks. During cross-linking of 
the tissue in glutaraldehyde, wechecked the concentration 
of glutaraldehyde in the preservative solution every sev- 
enth day and compared it with that of fresh solution 
spectrophotometrically fter reacting with e-aminocap- 
roic acid. Because the concentration of glutaraldehyde 
was found to decrease in the preservative solution after 
the onset of preservation, the concentration of glutar- 
aldehyde in the preservative solution was increased 
gradually up to 0.25% over a period of more than 8 
weeks, until the concentration was the same as that of 
the fresh solution)'  4However, this period was less than 
4 weeks when the cross-linking was carried out at 
37 ° C. 5 According to our procedure, the cross-linking 
process of a tissue itself dictates the required concen- 
tration of glutaraldehyde and duration of the process at 
a particular temperature. 
The authors j presume that, with their technique, 
there is a possibility of limitation of calcification of 
glutaraldehyde-treated bioprosthetic valves (see Con- 
clusion). Dynamic fixation of bioprosthetic valves in 
glutaraldehyde may promote a better cross-linking pro- 
cess; however, our previous experience 3'4' 6 suggests 
that, short-term or prolonged, adequate or inadequate 
fixation would never change the pathologic feature of 
calcification of bioprostheses when only glutaraldehyde 
treatment is concerned. 
Jyotirmay Chanda, MD 
Ryosei Kuribayashi, MD 
Tadaaki Abe, MD 
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